New combo therapy shows promise for rare leukemia
NCT ID NCT02523976
First seen Feb 13, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This study tested a drug called dasatinib combined with standard chemotherapy in 30 adults newly diagnosed with a specific, aggressive leukemia (Ph+ ALL). The goal was to see if the combination could improve survival and was tolerable. Participants took dasatinib daily for up to 2 years after achieving remission, and some also received a stem cell transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE,LEUKEMIA, LYMPHOID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.